Key messages

  • Dyspnoea, or breathlessness, is common in advanced illnesses like cancer, COPD, and heart failure, and is influenced by physiological factors (impaired gas exchange), psychological states (anxiety), and social or environmental contexts.
  • Assessing dyspnoea requires both subjective tools, such as the Borg Scale or RDOS, and objective measures like oxygen saturation, with special attention to non-verbal cues in cognitively impaired patients, such as those with dementia.
  • Non-pharmacological interventions, including fan therapy, breathing retraining techniques, and positioning strategies, are effective, low-cost methods for relieving dyspnoea and can be easily integrated into both hospital and home care settings.
  • Opioids, particularly morphine, remains to be the gold standard, pharmacological treatment for refractory dyspnoea, and work by reducing the brain's perception of respiratory discomfort. Benzodiazepines, corticosteroids, and anticholinergics can be used for specific cases based on underlying causes.
  • Family members and carers often face significant emotional and physical challenges when managing dyspnoea, making education on symptom management techniques and support from healthcare professionals is vital to reducing caregiver burden and anxiety.

Related Evidence

Suggest a tool

Have a favourite clinical tool not listed here? Contact us.

Definition and prevalence

Dyspnoea, or breathlessness, is often described as a subjective sensation of respiratory discomfort, typically manifesting as air hunger, chest tightness, or a feeling of suffocation. Given the multidimensional nature of dyspnoea, it can be challenging to manage effectively, particularly as the disease progresses. It is likely influenced by a combination of physiological factors, such as impaired gas exchange, psychological states like anxiety, and social contexts, such as social isolation. [1,2] Emotional responses, especially anxiety, exacerbate the perception of breathlessness, which can contribute to its complexity in palliative care settings. [3]

The prevalence of dyspnoea varies across advanced illnesses. In cancer patients, particularly those with thoracic malignancies, it is reported in approximately 70% of individuals, especially during the advanced stages. [1] For non-cancer patients, such as those living with chronic obstructive pulmonary disease (COPD) and heart failure, dyspnoea is also common, with estimates ranging from 50% to 100%. [4,5] However, the trajectory of dyspnoea may differ between these groups. In heart failure, for instance, the symptom could fluctuate based on fluid retention or physical exertion, whereas in cancer, it often intensifies gradually as the disease progresses towards the end of life. [2]

In chronic conditions like cystic fibrosis, dyspnoea tends to present earlier and may increase in intensity as lung function declines. [4] Patients with end-stage kidney disease also appear to experience breathlessness, often in the context of coexisting cardiovascular or respiratory conditions, though its prevalence is somewhat variable depending on the specific comorbidities. [5]


Assessment

Assessing dyspnoea in palliative care requires a combination of subjective and objective tools to address the complexity of this symptom. Commonly used subjective tools include the modified Borg Scale, Visual Analogue Scale (VAS), and the modified Medical Research Council (mMRC) Breathlessness Scale. These scales allow patients to rate the severity of their breathlessness, giving clinicians insight into how the symptom affects daily life and functioning. [1,5] The Borg Scale is often employed to quantify breathlessness on a scale from mild discomfort to severe distress, helping clinicians track changes over time. [5]

In addition to subjective assessments, objective measures such as oxygen saturation levels and respiratory rate are commonly used to assess the physiological impact of dyspnoea. [3] However, it is well documented that these physiological measures often do not correlate with the patient’s reported experience of breathlessness. [1] For instance, patients with advanced cancer may report severe dyspnoea even when their oxygen saturation levels remain normal, underscoring the need for a more comprehensive approach to assessment. [2]

Functional assessments, such as the six-minute walk test (6MWT), are sometimes employed to evaluate the impact of dyspnoea on physical activity. This test measures the distance a patient can walk in six minutes, providing insight into their endurance and how breathlessness limits their mobility. [5] However, this test may be unsuitable for many palliative care patients in advanced stages, as their mobility is often severely compromised. [4] In such cases, alternative assessments may be used either singularly or in conjunction with one another, such as evaluating whether the patient can speak in full sentences without difficulty or observing the use of accessory muscles for breathing. These complementary assessments offer a broader understanding of the severity of dyspnoea and can guide more appropriate interventions focused on comfort and symptom management.

Non-pharmacological treatment

Non-pharmacological interventions play a key role in managing dyspnoea in palliative care. Fan therapy involves directing cool air from a fan towards the patient’s face. This movement of air across the face stimulates the trigeminal nerve, reducing the sensation of air hunger. [6] It is a low-cost, non-invasive method that has shown quick effectiveness, with patients reporting relief within minutes of use. [6] This simple intervention is widely accepted and can be easily integrated into both hospital and home settings. [1]

Breathing retraining techniques such as pursed-lip breathing and diaphragmatic breathing are also commonly used. These methods help reduce the respiratory rate and improve breathing efficiency by focusing on controlled breathing patterns. They are often taught to patients to use during episodes of breathlessness, with the goal of reducing the sensation of dyspnoea. [3] These techniques are simple to teach and can be adapted for use in various palliative care settings. [4]

Positioning strategies, such as sitting upright or leaning forward, have also been shown to alleviate breathlessness by improving the mechanics of the diaphragm and reducing the work of breathing. These strategies are practical, require no special equipment, and can provide immediate relief, making them particularly useful in palliative care. [5] Patients and caregivers are often encouraged to experiment with different positions to find those that offer the most relief. [1]

Mindfulness and relaxation techniques, including guided breathing and meditation, are being increasingly integrated into dyspnoea management. These practices help to reduce anxiety, which can worsen the sensation of breathlessness. [7] By promoting a calm and controlled focus on breathing, mindfulness may alleviate patients' perception of dyspnoea. [7] Although more research is needed, these low-risk interventions hold promise when combined with other non-pharmacological approaches such as fan therapy and advanced respiratory support. Despite the varying quality of included studies, emerging evidence from systematic reviews supports the use of acupuncture, acupressure and reflexology for the improvement of breathlessness severity, exercise tolerance and quality of life. [8,9]

Pharmacological treatment

Opioids are widely regarded as the cornerstone for managing dyspnoea in palliative care, particularly when non-pharmacological interventions do not provide sufficient relief. [10] Morphine is the most commonly used opioid, administered either orally or subcutaneously, and works by decreasing the brain's perception of respiratory discomfort. [2] Opioids are thought to alter the central perception of breathlessness by reducing the respiratory drive, even in patients with normal oxygen levels. Starting doses of morphine are typically low and are carefully titrated based on patient response to minimise side effects such as sedation and constipation. [1] Regular reassessment of the dosage is important to ensure optimal symptom relief while mitigating the risk of adverse effects like respiratory depression. [3,11]

Benzodiazepines are often considered when anxiety exacerbates dyspnoea. These medications, such as lorazepam or midazolam, are used primarily for their anxiolytic effects rather than directly relieving breathlessness. While benzodiazepines may help reduce dyspnoea-related anxiety, evidence regarding their direct benefit in alleviating breathlessness is inconsistent, and they are typically used as a secondary option when opioids alone do not provide adequate symptom relief. [11,12] Short-acting benzodiazepines are preferred in the palliative setting due to their reduced risk of long-term sedation and delirium. [1] However, care must be taken to avoid respiratory depression when benzodiazepines are combined with opioids. [5]

Corticosteroids are sometimes employed when inflammation is a key contributor to dyspnoea, such as in cases of airway obstruction or pulmonary conditions. Dexamethasone, for example, can reduce airway oedema and improve airflow, providing symptomatic relief from breathlessness. [4,11] However, their use is usually limited to short-term management due to potential adverse effects like immunosuppression, muscle wasting, and hyperglycaemia. Additionally, oxygen therapy is commonly administered to patients with hypoxaemia but is less effective in those with normal oxygen levels, as studies suggest limited benefit in patients with normal oxygen levels. [11] When used in non-hypoxic palliative patients, the benefits of oxygen therapy such as the alleviation of patient and family distress needs to be considered against drawbacks including practical barriers associated with handling and transporting the oxygen equipment, restricted movement and mobility during use, and potentially increased caregiver load. [13] Anticholinergic agents, such as glycopyrrolate, are also used to manage excessive respiratory secretions contributing to dyspnoea, particularly in the terminal phase. [12]


Equity and access

Access to effective dyspnoea management in palliative care is shaped by social, cultural, and geographical factors, which can significantly affect treatment outcomes. In rural and remote regions of Australia, patients face considerable challenges in accessing specialised palliative care services. These areas often experience delays in the provision of essential treatments for dyspnoea, such as opioids and oxygen therapy, due to geographical isolation and limited availability of healthcare providers trained in managing complex symptoms like breathlessness. [14] While telehealth and mobile palliative care teams have been developed to address this gap, their availability remains inconsistent, and they may not always provide the rapid response required for acute dyspnoea management. [11] Moreover, the lack of access to in-person consultations can affect the timely assessment of dyspnoea severity, reducing the quality of care.

Culturally and linguistically diverse (CALD) populations are also at risk of unequal access to dyspnoea management. Language barriers, combined with differing cultural beliefs about breathlessness and end-of-life care, can lead to misunderstandings or delays in symptom recognition and treatment. [15] Patients from CALD backgrounds may be reluctant to use opioids due to concerns about addiction or negative cultural perceptions of pain medication, potentially leading to the undertreatment of breathlessness. [16] Furthermore, a lack of awareness about non-pharmacological interventions, such as fan therapy or positioning strategies, may limit their use. Overcoming these barriers requires healthcare providers to use culturally sensitive communication strategies, including the use of interpreters and culturally tailored education, to ensure that patients understand their treatment options and feel comfortable engaging in their care. [15]

Aboriginal and Torres Strait Islander peoples encounter unique challenges in accessing dyspnoea management. Many Indigenous communities are located in areas with limited healthcare infrastructure, which can delay access to both pharmacological and non-pharmacological treatments for breathlessness. [16] Historical mistrust of healthcare systems, combined with cultural beliefs about illness and death, may also hinder engagement with standard Western palliative care approaches. Indigenous populations often take a holistic view of health, incorporating spiritual and social elements into symptom management, making conventional treatments like opioids and oxygen therapy less acceptable without integration of traditional healing practices. [16] Adapting dyspnoea management to incorporate culturally appropriate practices, alongside conventional medical interventions, may improve treatment uptake and adherence in these communities.

Care context

Dyspnoea management in palliative care needs to be tailored to the care setting and specific patient population. In residential aged care homes, dyspnoea is particularly prevalent among residents with chronic conditions such as COPD, heart failure, or dementia. [5] Cognitive impairments, particularly in those with dementia, can make assessing dyspnoea challenging, as these individuals may be unable to communicate their discomfort verbally. In such cases, non-verbal cues like agitation or laboured breathing are essential in recognising breathlessness. [1] Tools such as the Respiratory Distress Observation Scale (RDOS) may assist in this process. Staff training in using these tools, along with non-pharmacological strategies like repositioning or fan therapy, is crucial in improving comfort for residents. [3]

In acute care settings, such as emergency departments (EDs) and intensive care units (ICUs), dyspnoea often presents acutely and requires rapid intervention. Pharmacological treatments, such as opioids, are commonly used to alleviate severe breathlessness, while non-pharmacological interventions, like positioning or fan therapy, can provide immediate relief alongside medical management. [2] Coordination between palliative care and acute care teams is essential to ensure that patients receive symptom relief in line with their broader care goals, particularly in end-of-life scenarios where invasive interventions may not be appropriate. [3]

Managing dyspnoea in people living with dementia presents additional complexities due to difficulties with communication. Non-verbal indicators, such as changes in breathing patterns or restlessness, become critical for assessing discomfort. [5] Non-pharmacological interventions, like fan therapy or repositioning, are often favoured to reduce the risk of further cognitive impairment or sedation. [1] When necessary, low-dose opioids may be used for more severe dyspnoea, but close monitoring is required to avoid side effects like sedation or respiratory depression. [3] A multidisciplinary approach, including palliative care specialists, nurses, and carers, helps ensure comprehensive care for managing dyspnoea in this population.

Implications for families and carers

Dyspnoea in palliative care places considerable emotional and practical burdens on families and carers. Witnessing a loved one struggling with breathlessness often leads to feelings of helplessness, especially when carers are unsure how to manage the symptoms effectively. [1] Acute episodes of dyspnoea heighten anxiety and contribute to caregiver burnout over time. As the frequency and severity of breathlessness increase, carers may find it increasingly difficult to cope with the growing demands of caregiving. [3,4]

Providing education and support to carers is crucial for reducing this burden. Training carers in non-pharmacological interventions, such as repositioning and fan therapy, enables them to assist with managing breathlessness, particularly in home care settings where immediate professional support is limited. [1,3] Carers who feel confident in applying these techniques are more likely to experience reduced anxiety and feel empowered in their caregiving role. Regular access to healthcare professionals for guidance and reassurance offers carers emotional support and increases their capacity to manage symptoms at home. [4]

Emotional support for carers is essential, especially as they often experience anticipatory grief as their loved one’s condition worsens. Open communication with healthcare teams provides practical advice and emotional reassurance, helping carers navigate the complexities of dyspnoea management. [1] A holistic approach, integrating symptom management with psychosocial support, helps reduce caregiver strain and ensures carers receive the support they need throughout the caregiving process. [3]

  1. Hui D, Bohlke K, Bao T, Campbell TC, Coyne PJ, Currow DC, et al. Management of dyspnea in advanced cancer: ASCO guideline. J Clin Oncol. 2021;39(12):1389-1411.
  2. Gaertner J, Fusi-Schmidhauser T, Stock S, Siemens W, Vennedey V. Effect of opioids for breathlessness in heart failure: A systematic review and meta-analysis. Heart. 2023;109(14):1064-1071.
  3. Feliciano JL, Waldfogel JM, Sharma R, Zhang A, Gupta A, Sedhom R, et al. Pharmacologic interventions for breathlessness in patients with advanced cancer: A systematic review and meta-analysis. JAMA Netw Open. 2021;4(2):e2037632.
  4. Jaiswal N, Singh M, Agarwal A, Chauhan A, Jaiswal N. Palliative drug treatments for breathlessness in cystic fibrosis. Cochrane Database Syst Rev. 2020;4(4):CD011855.
  5. Chilvers M, Johnston K, Ferrar K, Williams MT. Dyspnoea assessment in adults with end-stage kidney disease: A systematic review. J Ren Care. 2020;46(3):137-150.
  6. Kako J, Kobayashi M, Oosono Y, Kajiwara K, Miyashita M. Immediate effect of fan therapy in terminal cancer with dyspnea at rest: A meta-analysis. Am J Hosp Palliat Care. 2020;37(4):294-299.
  7. Nolan CM, Brighton LJ, Mo Y, Bayly J, Higginson IJ, Man WD, et al. Meditative movement for breathlessness in advanced COPD or cancer: A systematic review and meta-analysis. Eur Respir Rev. 2023;32(168):220243.
  8. Gupta A, Sedhom R, Sharma R, Zhang A, Waldfogel JM, Feliciano JL, et al. Nonpharmacological interventions for managing breathlessness in patients with advanced cancer: A systematic review. JAMA Oncol. 2021;7(2):290-298.
  9. von Trott P, Oei SL, Ramsenthaler C. Acupuncture for breathlessness in advanced diseases: A systematic review and meta-analysis. J Pain Symptom Manage. 2020;59(2):327-338.e323.
  10. Lowey S. Management of breathlessness at the end of life: A systematic review. J Pain Symptom Manage. 2022;63(5):868-869.
  11. Hasegawa T, Ochi T, Goya S, Matsuda Y, Kako J, Watanabe H, et al. Efficacy of supplemental oxygen for dyspnea relief in patients with advanced progressive illness: A systematic review and meta-analysis. Respir Investig. 2023;61(4):418-437.
  12. Luo N, Tan S, Li X, Singh S, Liu S, Chen C, et al. Efficacy and safety of opioids in treating cancer-related dyspnea: A systematic review and meta-analysis based on randomized controlled trials. J Pain Symptom Manage. 2021;61(1):198-210.e191.
  13. Kochovska S, Ferreira DH, Garcia MV, Phillips JL, Currow DC. Perspectives on palliative oxygen for breathlessness: Systematic review and meta-synthesis. Eur Respir J. 2021;58(4):2004613.
  14. Marshall C, Virdun C, Phillips JL. Evidence-based models of rural palliative care: A systematic review. Palliat Med. 2023;37(8):1129-1143.
  15. Burke C, Doody O, Lloyd B. Healthcare practitioners’ perspectives of providing palliative care to patients from culturally diverse backgrounds: A qualitative systematic review. BMC Palliat Care. 2023;22(1):182.
  16. Paterson C, Roberts C, Blackburn J, Jojo N, Northam HL, Wallis E, et al. Understanding the needs and preferences for cancer care among First Nations people: An integrative review. J Advan Nurs. 2024;80(5):1776-1812.

Last updated 05 December 2024